Complex regulation of telomerase activity: Implications for cancer therapy

American Journal of Pathology

Volumn 159, Issue 2, 2001, Pages 405-410

  Elenitoba Johnson, K S J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; TELOMERASE;

CANCER THERAPY; CHROMOSOME LOSS; DNA DEGRADATION; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME ANALYSIS; GERM CELL; HUMAN; MODULATION; NOTE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; T LYMPHOCYTE;

EID: 0034885864     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61710-5     Document Type: Note

References (71)

1. Specific association of human telomerase activity with immortal cells and cancer
2. Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents
3. Telomeres and their synthesis
4. Human telomeres are attached to the nuclear matrix
5. The roles of telomeres and telomerase in cell life span
6. Telomerase shorten with aging
7. The RNA component of human telomerase
8. A mammalian telomerase-associated protein
9. Human telomerase contains evolutionary conserved catalytic and structural subunits
10. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats
11. Telomerase activity is restored in human cells by ectopic expression of hTERT(hEST2), the catalytic subunit of telomerase
12. Telomerase catalytic subunit homologs from fission yeast and humans
13. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor
14. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells
15. Mechanism of telomerase induction during T cell activation
16. Telomere lengthening and telomerase activation during human B cell differentiation
17. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
18. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age
19. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter
20. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene
21. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA
22. Telomerase activation by the E6 gene product of human papillomavirus type 16
23. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation
24. Effect of oncogene expression on telomerase activation and telomere length in human endothelial, fibroblast and prostate epithelial cells
25. Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells
26. Bcl-2 modulates telomerase activity
27. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase
28. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit
29. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition
30. Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells
31. Adenovirus-mediated over-expression of p21Waf-1 differentially affects the proliferation, telomerase activity, and expression of glial fibrillary acidic protein in human glioma cells
32. Repression of the telomerase catalytic subunit by a gene on human chromosome 3 that induces cellular senescence
33. Telomerase repressor sequences on chromosome 3 and induction of permanent growth-arrest in human breast cancer cells
34. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development
35. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts
36. Frequent amplification of the telomerase reverse transcriptase gene in human tumors
37. Methylation of the human telomerase gene CpG island
38. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene
39. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor
40. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia
41. Interaction between dexamethasone and butyrate in apoptosis induction: Non-additive in thymocytes and synergistic in a T cell-derived leukemia cell line
42. Regulation of telomerase activity in immortal cell lines
43. Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro
44. Evidence for UV-associated activation of telomerase in human skin
45. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his)
46. Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development
47. Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer
48. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells
49. Telomerase is controlled by protein kinase C alpha in human breast cancer cells
50. Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation
51. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone
52. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells
53. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia
54. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture
55. Telomerase activity as a prognostic factor in neuroblastomas
56. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor
57. Telomere loss in cells treated with cisplatin
58. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
59. Suppression of telomerase activity in HL60 cells after treatment with differentiating agents
60. Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents
61. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells
62. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines
63. Cell cycle-dependent modulation of telomerase activity in tumor cells
64. Lack of cell cycle regulation of telomerase activity in human cells
65. Inhibition of telomerase limits the growth of human cancer cells
66. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
67. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase
68. Telomere dysfunction alters the chemotherapeutic profile of transformed cells
69. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
70. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)
71. Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: A simple blood test to monitor disease in cancer patients